ARWR
Arrowhead Pharmaceuticals Inc.

12,417
Mkt Cap
$8.67B
Volume
1.57M
52W High
$76.76
52W Low
$9.57
PE Ratio
-950.00
ARWR Fundamentals
Price
$64.02
Prev Close
$66.25
Open
$66.45
50D MA
$58.33
Beta
1.57
Avg. Volume
2.67M
EPS (Annual)
-$0.0122
P/B
18.59
Rev/Employee
$1.17M
Loading...
Loading...
News
all
press releases
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Acquired by Nordea Investment Management AB
Nordea Investment Management AB boosted its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 74.5% during the third quarter, according to its most recent Form 13F...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
SG Americas Securities LLC Boosts Stake in Arrowhead Pharmaceuticals, Inc. $ARWR
SG Americas Securities LLC grew its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 418.1% during the 3rd quarter, according to the company in its most recent...
MarketBeat·2d ago
News Placeholder
Arrowhead Pharmaceuticals Touts Rudemplo Launch, Obesity RNAi Data and $920M Cash at JPM Conference
Arrowhead Pharmaceuticals (NASDAQ:ARWR) used its presentation at the JPMorgan Healthcare Conference to highlight a newly launched RNA interference (RNAi) therapy, a broad clinical-stage pipeline, and...
MarketBeat·6d ago
News Placeholder
Is Arrowhead Pharmaceuticals Stock a Buy or Sell After the CEO Sold Shares Worth $5.4 Million?
Key PointsCEO Christopher Anzalone sold 85,000 shares in the open market on Dec. 17, 2025, for a transaction value of ~$5,443,462...
Nasdaq News: Markets·8d ago
News Placeholder
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Chinese National Medical Products Administration (NMPA) has approved REDEMPLO (plozasiran) for the reduction of triglyceride...
Business Wire·11d ago
News Placeholder
Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its intention to offer, subject to market and other conditions, $500 million aggregate principal amount of convertible senior notes due...
Business Wire·12d ago
News Placeholder
Arrowhead Pharmaceuticals Shares Early RNAi Obesity Data, Highlights Visceral Fat Drops and Combo Potential
Arrowhead Pharmaceuticals (NASDAQ:ARWR) shared initial interim clinical results from two RNA interference (RNAi) obesity candidates, ARO-INHBE and ARO-ALK7, during a virtual key opinion leader (KOL...
MarketBeat·12d ago
News Placeholder
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 52-Week High - Time to Buy?
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 1-Year High - Here's What Happened...
MarketBeat·12d ago
News Placeholder
Arrowhead Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:ARWR)
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) saw some unusual options trading on Tuesday. Traders purchased 5,093 call options on the company. This represents an increase of...
MarketBeat·12d ago
News Placeholder
Arrowhead Obesity Drugs Show Significant Fat Loss In Early Human Trials
Arrowhead Pharmaceuticals reported early trial data showing notable reductions in body, liver, and visceral fat from two experimental obesity drugs, with more results expected in 2026.read more...
Benzinga·12d ago
<
1
2
...
>

Latest ARWR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.